All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-CEA chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target human CEA. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CEA antibody linked to 4-1BB and CD3ζ signaling domains. And the vector product was designed for the treatment of CEA positive cancers.
CAR Construction : Fig.1 Flow-cytometric analysis comparing the binding specificity of humanised PR1A3. No specific binding was observed with the isotyped-matched irrelevant control antibody. Stewart, L. M., Young, S., Watson, G., Mather, S. J., Bates, P. A., Band, H. A., ... & Snary, D. (1999). Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 47(6), 299-306. |
CAR Construction : Fig.2 Binding of technetium99m-labelled humanised PR1A3 to live MKN45 cells. The curves are fitted by non-linear least-squares analysis. Stewart, L. M., Young, S., Watson, G., Mather, S. J., Bates, P. A., Band, H. A., ... & Snary, D. (1999). Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunology, Immunotherapy, 47(6), 299-306. |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-CEA (hMN-14) h(4-1BB-CD3ζ) CAR, pCDCAR1 (CAR-YF030). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION